Novel 2-Phenyl-1H-Pyrrole Derivatives as Mitochondrial Pyruvate Carrier Inhibitors to Treat Hair Loss

Xingyu Wu1,2,3, Han Zhang1,2, Yilei Huang1,2

  • 1Shanghai Institute of Pharmaceutical Industry Co., Ltd., China State Institute of Pharmaceutical Industry, Shanghai, China.

Insights

New compounds targeting the mitochondrial pyruvate carrier (MPC) activate hair follicle stem cells (HFSCs) to promote hair regrowth. Compound 5a shows promise as a safe and effective topical treatment for hair loss.

Area of Science:

  • Biochemistry
  • Dermatology
  • Stem Cell Biology

Background:

  • Hair follicle stem cells (HFSCs) regulate the hair growth cycle.
  • Premature termination of the anagen phase leads to hair loss.
  • Mitochondrial pyruvate carrier (MPC) inhibition enhances lactate synthesis, activating HFSCs.

Purpose of the Study:

  • To develop novel, safer, and more effective MPC inhibitors for hair loss treatment.
  • To design and synthesize 2-phenyl-1H-pyrrole derivatives as potential MPC inhibitors.
  • To evaluate the efficacy of these compounds in promoting hair regrowth.

Main Methods:

  • Scaffold hopping and structural optimization based on UK5099 and JXL066.
  • In vitro lactate release assays to identify potent compounds.
  • ADMET predictions and in vitro/in vivo testing for safety and efficacy.

Main Results:

  • 14 compounds showed superior biological activity to UK5099 in lactate release assays.
  • Compound 5a demonstrated potent activity, low toxicity, and moderate skin permeability.
  • 5a promoted hair regrowth in mice, increasing hair follicle density and accelerating the anagen phase.

Conclusions:

  • MPC is a viable therapeutic target for hair loss.
  • Compound 5a is a promising candidate for topical treatment of hair loss.
  • Further development of 5a could lead to effective hair loss therapies.

Related Concept Videos

Electron Transport Chain: Complex I and II01:46

Electron Transport Chain: Complex I and II

The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pyruvate Oxidation01:15

Pyruvate Oxidation

After glycolysis, the charged pyruvate molecules enter the mitochondria via active transport and undergo three enzymatic reactions. These reactions ensure that pyruvate can enter the next metabolic pathway so that energy stored in the pyruvate molecules can be harnessed by the cells.
First, the enzyme pyruvate dehydrogenase removes the carboxyl group from pyruvate and releases it as carbon dioxide. The stripped molecule is then oxidized and releases electrons, which are then picked up by NAD+...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Drugs Affecting Neurotransmitter Synthesis01:29

Drugs Affecting Neurotransmitter Synthesis

Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase, which converts...